Sunitinib malate shows promise against advanced form of lung cancer

Jun 5 2006

Results of a multi-center clinical study of a drug currently approved for treatment of kidney cancer indicate that it may also be effective for people with recurrent and advanced lung cancer.

The findings of this phase-2 clinical trial were presented at the American Society of Clinical Oncology (ASCO) meetings in Atlanta on Sunday (June 4).

Dr. Mark A. Socinski, associate professor of medicine at the University of North Carolina at Chapel Hill and a clinical faculty member of the UNC Lineberger Comprehensive Cancer Center, is the study's principal investigator. Socinski said the activity data on Pfizer's oral drug, sunitinib malate, appears "very similar" to that of other currently approved agents for non-small cell lung cancer.

Another drug, Avastin, keeps new blood vessels from forming and has been shown to help people with advanced lung cancer live longer when it was given along with chemotherapy.

Sunitinib, which is also an anti-angiogenic agent, interferes with a tumor cell's ability to develop new blood vessels. It acts on a molecular level by inhibiting an enzyme - tyrosine kinase - that activates cellular growth factor receptors, thus preventing further blood vessel growth.

"As a single agent, this drug worked in a difficult group of patients whose advanced disease had been previously treated with other chemotherapies and whose options were limited," Socinski said.

According to the UNC thoracic oncologist, among 63 patients treated, there were six confirmed partial responses, with disease stabilized in an additional 27. He said data as to length of survival "are still pending."

The patients were enrolled in the trial from January to October 2005. Treatment involved one 50-milligram oral dose (pill) per day for four weeks followed by two weeks off treatment, thus a six-week treatment cycle.

Adverse affects (toxicities) of the drug include fatigue, nausea, vomiting, abdominal pain and high blood pressure. Two patients developed a pulmonary hemorrhage and one a cerebral hemorrhage.

After the initial 63 patients, 47 more have been treated on a continuous dose of the drug, at 37.5 milligrams per day. This extension of the clinical trial will explore the effectiveness and safety of a continuous dosing strategy, Socinski said.